Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 4Sarcoma 3Gastrointestinal 3Other hematologic neoplasm 1Myeloid 1

Conditions

Gastrointestinal Stromal Tumors 15Neoplasms 3Sarcoma 1Retroperitoneal liposarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Neoplasm Metastasis 1Liposarcoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyosarcoma 1Gastrointestinal Neoplasms 1Disease Progression 1Chordoma 1Chondrosarcoma 1

Interventions

Cyclophosphamide 17pembrolizumab 12Doxorubicin 10fludarabine 7Irinotecan 7Blood Specimen Collection 7Temozolomide 6Gemcitabine 6Etoposide 6Radiotherapy 5Ifosfamide 5Carboplatin 5Albumin-Bound Paclitaxel 5tecogalan 4cemiplimab 4Vincristine 4Trabectedin 4Paclitaxel 4Nivolumab 4Filgrastim 4Drug Therapy 4Dexamethasone 4Bevacizumab 4pazopanib 3olaparib 3nilotinib 3dostarlimab 3aflibercept 3Therapeutics 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × nilotinib × Sarcoma × Clear all
NCT01863745 2024-08-19

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Novartis

Phase 2 Completed
15 enrolled 7 charts
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT01289028 2017-01-02

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

Novartis

Phase 3 Completed
125 enrolled 11 charts
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Novartis

Phase 1 Completed
14 enrolled
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡